We are live on
!
Find out more
DTC
Deep Track Capital Portfolio holdings
AUM
$4.85B
1-Year Est. Return
144%
This Fund
S&P 500
1 Year Est. Return
+144%
AUM
$4.85B
AUM Growth
+$462M
(+11%)
Holding
69
Top Buys
| 1 | +$169M | |
| 2 | +$140M | |
| 3 | +$111M | |
| 4 |
Genmab
GMAB
|
+$110M |
| 5 |
Vera Therapeutics
VERA
|
+$55.4M |
Top Sells
| 1 | +$242M | |
| 2 | +$125M | |
| 3 | +$69.3M | |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$67.1M |
| 5 |
MAZE
Maze Therapeutics
MAZE
|
+$33.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Guardant Health
GH
$17.5B
| $308M | 6.36% |
3,338,241
+538,241
|
|
||
2
Immunovant
IMVT
$6.9B
| $286M | 5.91% |
11,526,971
|
|
||
3
Tarsus Pharmaceuticals
TARS
$2.67B
| $253M | 5.21% |
3,600,000
+595,966
|
|
||
4
Vaxcyte
PCVX
$6.85B
| $250M | 5.16% |
4,300,000
+300,000
|
|
||
5
Structure Therapeutics
GPCR
$3.05B
| $206M | 4.26% |
4,279,848
+168,066
|
|
||
6
Axsome Therapeutics
AXSM
$13.1B
| $186M | 3.84% |
1,100,000
-50,000
|
|
||
|
APLS
7
DELISTED
Apellis Pharmaceuticals
APLS
| $182M | 3.76% |
4,532,374
-3,217,626
|
|
||
8
Ocular Therapeutix
OCUL
$1.96B
| $167M | 3.44% |
19,686,282
+11,615,868
|
|
||
|
9
Vera Therapeutics
VERA
$2.46B
| $165M | 3.41% |
4,106,067
+1,284,932
|
|
||
|
ALMS
10
Alumis Inc
ALMS
$3.08B
| $149M | 3.08% |
+6,772,595
|
|
||
11
Ionis Pharmaceuticals
IONS
$12.1B
| $146M | 3.02% |
1,950,000
+250,000
|
|
||
12
Nuvalent
NUVL
$9.75B
| $141M | 2.91% |
+1,376,324
|
|
||
13
Alkermes
ALKS
$7.38B
| $127M | 2.62% |
3,590,323
+1,590,323
|
|
||
|
CNTA
14
Centessa Pharmaceuticals
CNTA
$6.15B
| $125M | 2.59% |
3,158,041
+1,158,041
|
|
||
15
MoonLake Immunotherapeutics
MLTX
$1.38B
| $119M | 2.47% |
6,408,863
+1,798,792
|
|
||
|
MAZE
16
Maze Therapeutics
MAZE
$1.33B
| $104M | 2.14% |
3,477,562
-768,878
|
|
||
|
ORKA
17
Oruka Therapeutics
ORKA
$4.22B
| $99.8M | 2.06% |
2,034,203
-127,307
|
|
||
18
Nurix Therapeutics
NRIX
$1.75B
| $98.4M | 2.03% |
6,345,244
-691,211
|
|
||
|
19
Genmab
GMAB
$15.4B
| $98.3M | 2.03% |
+3,663,250
|
|
||
20
Cytokinetics
CYTK
$9.52B
| $90.6M | 1.87% |
1,374,320
-1,962,678
|
|
||
|
GRAL
21
GRAIL Inc
GRAL
$2.57B
| $89M | 1.84% |
1,722,797
+700,000
|
|
||
|
LBRX
22
LB Pharmaceuticals
LBRX
$815M
| $82.7M | 1.71% |
3,352,804
|
|
||
|
MBX
23
MBX Biosciences
MBX
$1.69B
| $82.3M | 1.7% |
2,757,569
-492,221
|
|
||
|
BCAX
24
Bicara Therapeutics
BCAX
$1.43B
| $80.8M | 1.67% |
4,062,500
+1,448,496
|
|
||
|
CMPS
25
Compass Pathways
CMPS
$1.63B
| $67.3M | 1.39% |
12,161,496
+4,827,173
|
|